EUVIMEDEUVIMED entdecken
Netzwerk-MetaanalyseSystematische Übersicht

Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis

Arya Babul iD, Devina Mehta iD, Yssra Soliman iD, Momina Hussain iD, Najib Babul iD

International Journal of Dermatology · 2026

DOI: 10.1111/ijd.70228 ↗

Kurz gefasst

Netzwerk-Metaanalyse in der Zeitschrift International Journal of Dermatology, 2026. Verfasst von Arya Babul und 4 weiteren Autor:innen. Beteiligte Einrichtung: West Career & Technical Academy, and Society for Awareness of Neglected Diseases, Las Vegas, Nevada, USA. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Heterocyclic Compounds, 3-Ring. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 81 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Janus kinase inhibitors (JAKis) have revolutionized the management of moderate‐to‐severe atopic dermatitis (AD). Although agents approved by the United States Food and Drug Administration (FDA), such as upadacitinib and abrocitinib, are widely used, and baricitinib and ivarmacitinib are under investigation, direct head‐to‐head randomized clinical trials (RCTs) comparing these agents are lacking.

Objective

Our aim was to rank the short‐term efficacy of four oral JAKis, upadacitinib (15/30 mg), abrocitinib (100/200 mg), baricitinib (2/4 mg), and ivarmacitinib (4/8 mg), in moderate‐to‐severe AD using a Bayesian Network Meta‐Analysis (BNMA).

Methods

Conducted per PRISMA 2020 guidelines and registered in PROSPERO (CRD420251116775), this study systematically reviewed phase 2 and 3 RCTs evaluating JAKi monotherapy in adults with moderate‐to‐severe AD. Primary endpoints included: (1) ≥ 75% improvement in Eczema Area and Severity Index (EASI‐75), (2) Investigator's Global Assessment (IGA‐ AD 0/1), and (3) ≥ 4‐point reduction in itch numeric rating scale (Itch NRS) at 12–16 weeks. Bayesian hierarchical modeling estimated odds ratios (ORs) with 95% credible intervals (CrIs), and surface under the cumulative ranking curve (SUCRA) probabilities defined the treatment hierarchy.

Results

Nine RCTs ( n = 4261) were included. Upadacitinib 30 mg demonstrated the greatest efficacy across all endpoints, EASI‐75 (OR = 12.3; 95% CrI 7.9–18.7), IGA‐ AD 0/1 (OR = 18.9; 95% CrI 12.0–29.7), and Itch NRS (OR = 11.1; 95% CrI 7.2–17.5), followed by upadacitinib 15 mg, abrocitinib 200 mg, and ivarmacitinib 8 mg. Baricitinib 2 mg and 4 mg consistently ranked lowest. SUCRA values confirmed upadacitinib 30 mg as the top performer (97%–98%).

Conclusion

Among oral JAKis, upadacitinib 30 mg, followed by upadacitinib 15 mg, achieved the most consistent short‐term efficacy, providing superior skin clearance and itch relief. Abrocitinib 200 mg and ivarmacitinib 8 mg showed intermediate benefits, whereas baricitinib displayed modest effects. These findings support a provisional efficacy preference for upadacitinib in managing moderate‐to‐severe AD unresponsive to biologic or topical therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicJanus Kinase InhibitorsHeterocyclic Compounds, 3-RingHumansBayes TheoremAzetidinesSeverity of Illness IndexPyrazolesPurinesPyrimidinesRandomized Controlled Trials as TopicTreatment OutcomeSulfonamides

Stichwörter der Autor:innen

Bayesian network meta‐analysisJAK inhibitorsabrocitinibatopic dermatitisbaricitinibivarmacitinibupadacitinib

Substanzen

upadacitinibJanus Kinase InhibitorsbaricitinibAzetidinesHeterocyclic Compounds, 3-RingPyrazolesPurinesabrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • West Career & Technical Academy, and Society for Awareness of Neglected Diseases, Las Vegas, Nevada, USA.
  • General, Surgical, and Cosmetic Dermatology, Thomas Dermatology, Las Vegas, Nevada, USA.
  • Genomics Department, Chinese Academy of Tropical Agriculture Sciences, Sanya, China.
  • Cinergen LLC, Las Vegas, Nevada, USA.

ORCID-Profile: Arya Babul, Devina Mehta, Yssra Soliman, Momina Hussain, Najib Babul

Zitieren

APA

Babul, A., Mehta, D., Soliman, Y., Hussain, M., & Babul, N. (2026). Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. https://doi.org/10.1111/ijd.70228

Vancouver

Babul A, Mehta D, Soliman Y, Hussain M, Babul N. Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis. International Journal of Dermatology. 2026. doi:10.1111/ijd.70228

BibTeX
@article{Babul2026,
  author = {Babul, Arya and Mehta, Devina and Soliman, Yssra and Hussain, Momina and Babul, Najib},
  title = {Upadacitinib Leads in Efficacy: A Bayesian Network Meta‐Analysis of Four JAK Inhibitors in Moderate‐To‐Severe Atopic Dermatitis},
  journal = {International Journal of Dermatology},
  year = {2026},
  doi = {10.1111/ijd.70228}
}
Kostenlos starten →